 Context Therapeutics NASDAQ:CNTX Inc announced that it has ended its first quarter of 2022 with 45.7 million in cash and equivalents as of March 31, which the company says should be sufficient to fund its operations into 2024. The womens oncology company also noted that 2022 looks to be a pivotal year as it anticipates reporting preliminary data of ONA-XR from ongoing Phase 2 trials in breast, ovarian, and endometrial cancers later in the year. 